Noninvasive Approaches to Detect Methylation-based Markers to Monitor Gliomas

Overview

Journal Neurooncol Adv

Publisher Oxford University Press

Date 2022 Nov 16

PMID 36380867

Authors

Houtan Noushmehr

Grayson Herrgott

Natalia S Morosini

Ana Valeria Castro

Affiliations

Soon will be listed here.

Abstract

In this review, we summarize the current approaches used to detect glioma tissue-derived DNA methylation markers in liquid biopsy specimens with the aim to diagnose, prognosticate and potentially track treatment response and evolution of patients with gliomas.

Citing Articles

Identifying targeted cell-free DNA methylation regions in head and neck cancer via paired methylome analysis.

Li T, Patel K, Yu X, Yao S, Wang L, Chung C Res Sq. 2024; .

PMID: 39649173 PMC: 11623779. DOI: 10.21203/rs.3.rs-5124805/v1.

The role of aberrant DNA methylation in cancer initiation and clinical impacts.

Geissler F, Nesic K, Kondrashova O, Dobrovic A, Swisher E, Scott C Ther Adv Med Oncol. 2024; 16:17588359231220511.

PMID: 38293277 PMC: 10826407. DOI: 10.1177/17588359231220511.

Unmet need for liquid biomarkers and the Brain-Liquid Biopsy Consortium.

Short S, Noushmehr H Neurooncol Adv. 2022; 4(Suppl 2):ii1-ii3.

PMID: 36380869 PMC: 9650471. DOI: 10.1093/noajnl/vdac020.

References

Mouliere F, Mair R, Chandrananda D, Marass F, Smith C, Su J . Detection of cell-free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients. EMBO Mol Med. 2018; 10(12). PMC: 6284385. DOI: 10.15252/emmm.201809323. View

Wood M, Halfpenny A, Moore S . Applications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular entities. Diagn Pathol. 2019; 14(1):29. PMC: 6457044. DOI: 10.1186/s13000-019-0802-8. View

Tesileanu C, van den Bent M, Sanson M, Wick W, Brandes A, Clement P . Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. Neuro Oncol. 2021; 23(9):1547-1559. PMC: 8408862. DOI: 10.1093/neuonc/noab088. View

Ceccarelli M, Barthel F, Malta T, Sabedot T, Salama S, Murray B . Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell. 2016; 164(3):550-63. PMC: 4754110. DOI: 10.1016/j.cell.2015.12.028. View

Kukreja L, Li C, Ezhilan S, Iyer V, Kuo J . Emerging Epigenetic Therapies for Brain Tumors. Neuromolecular Med. 2021; 24(1):41-49. DOI: 10.1007/s12017-021-08691-x. View

El Messaoudi S, Rolet F, Mouliere F, Thierry A . Circulating cell free DNA: Preanalytical considerations. Clin Chim Acta. 2013; 424:222-30. DOI: 10.1016/j.cca.2013.05.022. View

Mouliere F, Smith C, Heider K, Su J, van der Pol Y, Thompson M . Fragmentation patterns and personalized sequencing of cell-free DNA in urine and plasma of glioma patients. EMBO Mol Med. 2021; 13(8):e12881. PMC: 8350897. DOI: 10.15252/emmm.202012881. View

Louis D, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6):803-20. DOI: 10.1007/s00401-016-1545-1. View

Fiano V, Trevisan M, Trevisan E, Senetta R, Castiglione A, Sacerdote C . MGMT promoter methylation in plasma of glioma patients receiving temozolomide. J Neurooncol. 2014; 117(2):347-57. DOI: 10.1007/s11060-014-1395-4. View

10.

Warton K, Graham L, Yuwono N, Samimi G . Comparison of 4 commercial kits for the extraction of circulating DNA from plasma. Cancer Genet. 2018; 228-229:143-150. DOI: 10.1016/j.cancergen.2018.02.004. View

11.

Capper D, Stichel D, Sahm F, Jones D, Schrimpf D, Sill M . Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. Acta Neuropathol. 2018; 136(2):181-210. PMC: 6060790. DOI: 10.1007/s00401-018-1879-y. View

12.

Meddeb R, Pisareva E, Thierry A . Guidelines for the Preanalytical Conditions for Analyzing Circulating Cell-Free DNA. Clin Chem. 2019; 65(5):623-633. DOI: 10.1373/clinchem.2018.298323. View

13.

Li W, Zhang X, Lu X, You L, Song Y, Luo Z . 5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers. Cell Res. 2017; 27(10):1243-1257. PMC: 5630683. DOI: 10.1038/cr.2017.121. View

14.

Koval A, Blagodatskikh K, Kushlinskii N, Shcherbo D . The Detection of Cancer Epigenetic Traces in Cell-Free DNA. Front Oncol. 2021; 11:662094. PMC: 8118693. DOI: 10.3389/fonc.2021.662094. View

15.

Sareen H, Garrett C, Lynch D, Powter B, Brungs D, Cooper A . The Role of Liquid Biopsies in Detecting Molecular Tumor Biomarkers in Brain Cancer Patients. Cancers (Basel). 2020; 12(7). PMC: 7408771. DOI: 10.3390/cancers12071831. View

16.

Lavon I, Refael M, Zelikovitch B, Shalom E, Siegal T . Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades. Neuro Oncol. 2010; 12(2):173-80. PMC: 2940579. DOI: 10.1093/neuonc/nop041. View

17.

Pan L, McClain L, Shaw P, Donnellan N, Chu T, Finegold D . Non-invasive epigenomic molecular phenotyping of the human brain via liquid biopsy of cerebrospinal fluid and next generation sequencing. Eur J Neurosci. 2020; 52(11):4536-4545. DOI: 10.1111/ejn.14997. View

18.

Bagley S, Nabavizadeh S, Mays J, Till J, Ware J, Levy S . Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study. Clin Cancer Res. 2019; 26(2):397-407. PMC: 6980766. DOI: 10.1158/1078-0432.CCR-19-2533. View

19.

de Souza C, Sabedot T, Malta T, Stetson L, Morozova O, Sokolov A . A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence. Cell Rep. 2018; 23(2):637-651. PMC: 8859991. DOI: 10.1016/j.celrep.2018.03.107. View

20.

Locke W, Guanzon D, Ma C, Liew Y, Duesing K, Fung K . DNA Methylation Cancer Biomarkers: Translation to the Clinic. Front Genet. 2019; 10:1150. PMC: 6870840. DOI: 10.3389/fgene.2019.01150. View